Advances in the support of patients with HIV include remarkable new pharmaceutical therapies, collaborative care, outstanding patient support, and medication management.
Experimental HIV vaccine could provide long-term protection in areas with high infection rates.
Researchers seek to determine the best antiretroviral treatment regimen for HIV.
Finding the right combinations for antiretroviral therapy for HIV remains a challenge for researchers.
Top news of the day from across the health care landscape.
Top news of the day from across the healthcare landscape.
New testing procedure can quickly evaluate HIV levels in the blood.
Optimal treatment to prevent mother-to-child transmission of HIV can increase adverse events.
Link between HIV and cancer established in new report.
In this week's "Around the Web," Pharmacy Times presents a video that was recently posted by the World Health Organization, which discusses self-testing options for HIV.
Newly developed technology maps HIV inserts across the human genome.
Around 14 million people have HIV worldwide – yet an estimated 40% don’t know they’re infected.
CDC officials now recommend routine use of the meningococcal conjugate vaccine for patients with HIV.
Study captures major changes in infectious diseases between 1980 through 2014.
The cost of providing essential medications may not be too costly in low- and middle-income countries.
December 1 is observed as World AIDS Day.
New progress made towards the development of an HIV vaccine.
Top news of the day from across the health care landscape.
Broadly neutralizing antibodies (bNAbs) may hold the key to eliminating HIV-1.
Individuals living with HIV have approximately a 50-50 chance of developing depression, which can cause adverse outcomes such as accelerated disease progression, suppressed immune function, and medication nonadherence.
A historic clinical trial testing the efficacy of an experimental HIV vaccine regimen gets underway this week in South Africa.
Launch of South Africa-based clinical trial provides hope for the defeat of HIV.
Stability of exhausted T cells in mice effects the durability of reinvigoration by PD-1 blockade.
Highly active antiretroviral therapy (HAART) prolongs survival for patients with HIV, but increases the risk for other chronic diseases.
Much research and literature has been devoted to cardiovascular diseases, neurocognitive diseases, and neuroendocrine dysfunction in the aging patient with HIV, but cancer in patients with HIV is also a growing concern.
